Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000591389 | SCV000708289 | uncertain significance | not provided | 2017-05-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000591389 | SCV001990812 | uncertain significance | not provided | 2019-04-02 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes splice predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Located in the A-band of the titin protein, where the majority of pathogenic truncating variants have been reported; Missense variant in a gene in which most reported pathogenic variants are truncating/loss-of-function |
Ambry Genetics | RCV002341532 | SCV002643507 | uncertain significance | Cardiovascular phenotype | 2019-08-13 | criteria provided, single submitter | clinical testing | The p.I16618V variant (also known as c.49852A>G), located in coding exon 153 of the TTN gene, results from an A to G substitution at nucleotide position 49852. The isoleucine at codon 16618 is replaced by valine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species; however, valine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000591389 | SCV003825597 | uncertain significance | not provided | 2022-06-10 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000591389 | SCV004225811 | uncertain significance | not provided | 2023-05-01 | criteria provided, single submitter | clinical testing | BP4 |